Adempas and Ocular hyperaemia - a phase IV clinical study of FDA data

Summary:

Ocular hyperaemia is found among people who take Adempas, especially for people who are female, 60+ old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Adempas and have Ocular hyperaemia. It is created by eHealthMe based on reports of 24,196 people who have side effects when taking Adempas from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Nov, 24, 2022

24,196 people reported to have side effects when taking Adempas.
Among them, 76 people (0.31%) have Ocular hyperaemia.


What is Adempas?

Adempas has active ingredients of riociguat. eHealthMe is studying from 24,209 Adempas users for its effectiveness, alternative drugs and more.

What is Ocular hyperaemia?

Ocular hyperaemia (an abnormally large amount of blood in eye) is found to be associated with 1,842 drugs and 1,407 conditions by eHealthMe.

Number of Adempas and Ocular hyperaemia reports submitted per year:

Could Adempas cause Ocular hyperaemia?

Time on Adempas when people have Ocular hyperaemia *:

  • < 1 month: 100 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Ocular hyperaemia when taking Adempas *:

  • female: 88.16 %
  • male: 11.84 %

Age of people who have Ocular hyperaemia when taking Adempas *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 10.77 %
  • 40-49: 10.77 %
  • 50-59: 10.77 %
  • 60+: 67.69 %

Common drugs people take besides Adempas *:

  1. Opsumit: 27 people, 35.53%
  2. Coumadin: 17 people, 22.37%
  3. Letairis: 13 people, 17.11%
  4. Amlodipine: 12 people, 15.79%
  5. Ventavis: 11 people, 14.47%
  6. Eliquis: 10 people, 13.16%
  7. Veletri: 10 people, 13.16%
  8. Uptravi: 10 people, 13.16%
  9. Tracleer: 10 people, 13.16%
  10. Ambrisentan: 9 people, 11.84%

Common side effects people have besides Ocular hyperaemia *:

  1. Headache (pain in head): 44 people, 57.89%
  2. Breathing Difficulty: 41 people, 53.95%
  3. Hypotension (abnormally low blood pressure): 28 people, 36.84%
  4. Diarrhea: 26 people, 34.21%
  5. Nausea (feeling of having an urge to vomit): 25 people, 32.89%
  6. Pain In Jaw: 25 people, 32.89%
  7. Pain: 23 people, 30.26%
  8. Dizziness: 23 people, 30.26%
  9. Weakness: 22 people, 28.95%
  10. Indigestion: 22 people, 28.95%

Common conditions people have *:

  1. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 61 people, 80.26%
  2. Pulmonary Hypertension (increase in blood pressure in the lung artery): 17 people, 22.37%
  3. Heart Palpitations (feelings or sensations that your heart is pounding or racing): 2 people, 2.63%
  4. Sleep Disorder: 1 person, 1.32%
  5. Pulmonary Embolism (blockage of the main artery of the lung): 1 person, 1.32%

* Approximation only. Some reports may have incomplete information.

Do you take Adempas and have Ocular hyperaemia?

Check whether Ocular hyperaemia is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

How severe was Ocular hyperaemia and when was it recovered:

Expand to all the drugs that have ingredients of riociguat:

Alternative drugs to, pros and cons of Adempas:

Common Adempas side effects:

Browse all side effects of Adempas:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Ocular hyperaemia treatments and more:

COVID vaccines that are related to Ocular hyperaemia:

Common drugs associated with Ocular hyperaemia:

All the drugs that are associated with Ocular hyperaemia:

Common conditions associated with Ocular hyperaemia:

All the conditions that are associated with Ocular hyperaemia:

How the study uses the data?

The study uses data from the FDA. It is based on riociguat (the active ingredients of Adempas) and Adempas (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: